Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Seminars in Cancer Biology
|
June 11, 2021
Precision medicine in pediatric solid cancers
Mirjam Blattner-Johnson, David T W Jones, Elke Pfaff
Acta Neuropathologica Communications
|
November 26, 2025
Recurrent genetic alterations in epigenetically defined pineoblastoma subtypes
Tobias Goschzik, Mathias Yuan, Elke Pfaff, et al.
JCO Precision Oncology
|
January 7, 2022
<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets
Elke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, et al.
Journal of Neuro-Oncology
|
January 22, 2024
Pineal anlage tumor: clinical and diagnostic features, and rationales for treatment
Denise Obrecht-Sturm, Elke Pfaff, Martin Mynarek, et al.
Neuro-Oncology
|
October 3, 2018
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
Wolfgang Wick, Susan Dettmer, Anne Berberich, et al.
Cancer Treatment and Research Communications
|
September 11, 2025
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial
Christoph E Heilig, Christoph Heining, Editha Gnutzmann, et al.
Neuro-Oncology
|
November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study
Elke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma
Elke Pfaff, Marc Remke, Dominik Sturm, et al.
BMC Cancer
|
June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
Cornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Neuro-Oncology
|
July 29, 2024
SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors
Anthony P Y Liu, Bryan K Li, Alexandre Vasiljevic, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Seminars in Cancer Biology
|
June 11, 2021
Precision medicine in pediatric solid cancers
Mirjam Blattner-Johnson, David T W Jones, Elke Pfaff
Acta Neuropathologica Communications
|
November 26, 2025
Recurrent genetic alterations in epigenetically defined pineoblastoma subtypes
Tobias Goschzik, Mathias Yuan, Elke Pfaff, et al.
JCO Precision Oncology
|
January 7, 2022
<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets
Elke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, et al.
Journal of Neuro-Oncology
|
January 22, 2024
Pineal anlage tumor: clinical and diagnostic features, and rationales for treatment
Denise Obrecht-Sturm, Elke Pfaff, Martin Mynarek, et al.
Neuro-Oncology
|
October 3, 2018
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
Wolfgang Wick, Susan Dettmer, Anne Berberich, et al.
Cancer Treatment and Research Communications
|
September 11, 2025
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial
Christoph E Heilig, Christoph Heining, Editha Gnutzmann, et al.
Neuro-Oncology
|
November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study
Elke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma
Elke Pfaff, Marc Remke, Dominik Sturm, et al.
BMC Cancer
|
June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
Cornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Neuro-Oncology
|
July 29, 2024
SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors
Anthony P Y Liu, Bryan K Li, Alexandre Vasiljevic, et al.
Page
of 5